title: Clinical study of the efficiency and safety of afala in patients with benign prostatic hyperplasia.
abstract: The use of afala in patients with benign prostatic hyperplasia and moderate urination disturbances reduced the symptoms of the disease, improved urodynamic parameters, and increased quality of life. Clinical efficiency of afala was comparable with the efficiency of Serenoa repens extract (reference preparation).
authors.affiliation: Materia Medica Holding Research-and-Production Company, Moscow.
authors.forename: K V
authors.initials: KV
authors.lastname: Savel'eva
authors.forename: M V
authors.initials: MV
authors.lastname: Kachanova
authors.forename: V N
authors.initials: VN
authors.lastname: Pavlov
authors.forename: R A
authors.initials: RA
authors.lastname: Kazikhinurov
authors.forename: M Yu
authors.initials: MY
authors.lastname: Frolov
authors.forename: A B
authors.initials: AB
authors.lastname: Mukhin
authors.forename: V V
authors.initials: VV
authors.lastname: Udut
authors.forename: Z A
authors.initials: ZA
authors.lastname: Yurmazov
authors.forename: Yu L
authors.initials: YL
authors.lastname: Dugina
authors.forename: S A
authors.initials: SA
authors.lastname: Sergeeva
authors.forename: O I
authors.initials: OI
authors.lastname: Epshtein
mesh_terms: D000328:Adult; D000368:Aged; D000906:Antibodies / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life; D016896:Treatment Outcome; D014563:Urodynamics / Q000187:drug effects
chemical_list: D000906:Antibodies; D007155:Immunologic Factors; C533336:afala